Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

New liquid biopsy test confirms remission in patients with HPV-associated oropharyngeal cancer

A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma are free from cancer following radiation therapy.

23 Oct 2018

Novel blood test shows promise for monitoring HPV-linked head and neck cancer after treatment

A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.

23 Oct 2018

Patient Outcomes of Prostate Cancer with Whole Slide Imaging

An interview with Dr.

From Huron Technologies 23 Oct 2018

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Oncology trial RTOG 0232 comparing a combined treatment of external beam therapy and brachytherapy to transperineal interstitial permanent brachytherapy alone indicate a significantly different clinician and patient-reported late toxicity profile between arms despite similarities in progression-free survival results.

22 Oct 2018

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.

22 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.

22 Oct 2018

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.

22 Oct 2018

Breast Cancer as a Dynamic Disease

An interview with Dr. Andrew Ewald, discussing the influence of the myoepithelium on breast cancer growth and the importance of studying metastasis.

19 Oct 2018

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Researchers at La Jolla Institute for Immunology and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute's Cancer Moonshot initiative.

19 Oct 2018

Sleeping Beauty technique helps identify genes responsible for NAFLD-associated liver cancer

With an estimated twenty-thousand protein-coding genes in the human genome, pinpointing a specific gene or pathway responsible for a particular disease can be like finding a needle in the proverbial haystack.

17 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Researchers identify basic relationships of cell cycle and cellular senescence in the placenta

Working with researchers from Stanford University and St. Anna Children's Cancer Research, researchers from Jürgen Pollheimer's laboratory at the Medical University of Vienna's Department of Obstetrics and Gynecology have now, for the first time, identified basic relationships of the cell cycle and cellular senescence in the human placenta.

15 Oct 2018

Scientists shed light on roles of transcription factors, TP63 and SOX2, in squamous cell carcinoma

Squamous cell carcinomas are aggressive malignancies arising from squamous epithelium of various organs, such as esophagus, head and neck, lung and skin. Previous studies demonstrated that two master transcription factors, TP63 and SOX2, effect genomic activation in SCCs.

15 Oct 2018

Carcinoma News and Research

Further Reading

New liquid biopsy test confirms remission in patients with HPV-associated oropharyngeal cancer

Novel blood test shows promise for monitoring HPV-linked head and neck cancer after treatment

Patient Outcomes of Prostate Cancer with Whole Slide Imaging

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

Breast Cancer as a Dynamic Disease

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Sleeping Beauty technique helps identify genes responsible for NAFLD-associated liver cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Researchers identify basic relationships of cell cycle and cellular senescence in the placenta

Scientists shed light on roles of transcription factors, TP63 and SOX2, in squamous cell carcinoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News